<DOC>
	<DOCNO>NCT02814825</DOCNO>
	<brief_summary>The purpose post-market study collect data ViviGen use affect fusion rate cervical spine use additional graft material fill cervical spacer . The patient population interest patient already elect undergo 2-3 level ACDF surgical procedure use ViviGen , per standard care .</brief_summary>
	<brief_title>An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix</brief_title>
	<detailed_description />
	<mesh_term>Spondylosis</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Candidates satisfy ALL following inclusion criterion consent participate study may consider eligible enrollment : 1 . Diagnosed investigator least one ( 1 ) following : Symptomatic cervical spondylosis ; Degenerative disc disease ( DDD ) , define discogenic pain degeneration disc confirm history imaging study ; Herniated nucleus pulposus ( HNP ) 2 . Subjects candidate already elect undergo contiguous two threelevel ACDF surgery C2C7 cervical spine 3 . Skeletally mature adult 21 75 year age 4 . Subjects , , opinion Investigator , able understand purpose study willing return require postoperative standard care followup visit data collect . Candidates meet ANY follow exclusion criterion consider eligible study participation : 1 . Posterior instrumentation necessary level treat 2 . Instability associate major reconstructive surgery primary tumor metastatic malignant tumor cervical spine 3 . Instability associate cervical spine trauma 4 . Acute chronic systemic localize spinal infection 5 . Previous deep anterior cervical surgery thyroid , carotid , high thoracic surgery ( T5 ) 6 . History previous cervical fusion surgery great one level 7 . Previous pseudoarthrosis level cervical spine 8 . Nursing mother woman pregnant plan become pregnant time study 9 . Severe osteoporosis ( per Investigator 's diagnosis per Tscore great equal 2.5 SD mean young , healthy adult ) may prevent adequate fixation screw thus preclude use cervical plate system 10 . Subjects know suspected allergy follow antibiotic and/or reagent : Gentamicin Sulfate , Meropenem , Vancomycin , Dimethyl Sulfoxide ( DMSO ) , Human Serum Albumin ( HSA ) 11 . Immune compromise subject 12 . Preexisting neurological abnormality deficit produce spinal fusion ( e.g . MS , Parkinson 's , CVA , diabetic neuropathy , peripheral neuropathy ) 13 . Conditions could preclude possibility fusion Investigator 's opinion ( e.g . cancer , kidney dialysis , smoking , uncontrolled diabetes , osteopenia ) 14 . History preoperative dysphagia 15 . Symptomatic shoulder pathology active treatment 16 . Known sensitivity device material 17 . Subjects , opinion Investigator , exist condition would compromise participation followup clinical study Intraoperative exclusion criterion : 18 . Intraoperative decision surgeon use implant compatible clear use ViviGen 19 . Intraoperative decision surgeon use bone graft substitute DBM rhBMP</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ViviGen</keyword>
	<keyword>ACDF</keyword>
	<keyword>Cervical</keyword>
</DOC>